X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Divis Laboratories with Orchid Chemicals - Equitymaster
  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

DIVIS LABORATORIES vs ORCHID PHARMA LTD - Comparison Results

DIVIS LABORATORIES    Change

Established in the year 1990, Divi's Laboratories has been focusing on CRAMS and is an established player in the custom chemical synthesis (CCS) and API/Intermediate segment. Around 50% of Divi's revenues are derived from custom manufacturing for glo... More

ORCHID PHARMA LTD 
   Change

Orchid Chemicals & Pharmaceuticals Ltd. (Orchid) is today a globally recognized, integrated pharmaceutical company with core competencies in the development and manufacture of Active Pharmaceutical Ingredients (APIs) and Finished Dosage Forms as well... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    DIVIS LABORATORIES ORCHID PHARMA LTD DIVIS LABORATORIES/
ORCHID PHARMA LTD
 
P/E (TTM) x 31.6 -0.7 - View Chart
P/BV x 5.5 0.5 1,167.2% View Chart
Dividend Yield % 0.9 0.0 -  

Financials

 DIVIS LABORATORIES   ORCHID PHARMA LTD
EQUITY SHARE DATA
    DIVIS LABORATORIES
Mar-17
ORCHID PHARMA LTD
Sep-13
DIVIS LABORATORIES/
ORCHID PHARMA LTD
5-Yr Chart
Click to enlarge
High Rs1,222194 629.9%   
Low Rs78435 2,240.0%   
Sales per share (Unadj.) Rs153.1276.5 55.4%  
Earnings per share (Unadj.) Rs39.9-79.2 -50.4%  
Cash flow per share (Unadj.) Rs44.6-43.5 -102.6%  
Dividends per share (Unadj.) Rs10.000-  
Dividend yield (eoy) %1.00-  
Book value per share (Unadj.) Rs201.853.9 374.2%  
Shares outstanding (eoy) m265.4770.45 376.8%   
Bonus/Rights/Conversions -ESOP-  
Price / Sales ratio x6.60.4 1,581.8%   
Avg P/E ratio x25.1-1.4 -1,737.0%  
P/CF ratio (eoy) x22.5-2.6 -853.6%  
Price / Book Value ratio x5.02.1 234.1%  
Dividend payout %25.00-   
Avg Mkt Cap Rs m266,2668,067 3,300.9%   
No. of employees `0009.72.8 347.7%   
Total wages/salary Rs m4,6872,527 185.5%   
Avg. sales/employee Rs Th4,175.06,956.1 60.0%   
Avg. wages/employee Rs Th481.5902.5 53.4%   
Avg. net profit/employee Rs Th1,089.3-1,993.0 -54.7%   
INCOME DATA
Net Sales Rs m40,64319,477 208.7%  
Other income Rs m749407 183.9%   
Total revenues Rs m41,39219,884 208.2%   
Gross profit Rs m14,4601,103 1,311.5%  
Depreciation Rs m1,2332,519 49.0%   
Interest Rs m235,227 0.4%   
Profit before tax Rs m13,953-6,236 -223.7%   
Minority Interest Rs m020 0.0%   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m0511 0.0%   
Tax Rs m3,349-125 -2,675.1%   
Profit after tax Rs m10,604-5,580 -190.0%  
Gross profit margin %35.65.7 628.5%  
Effective tax rate %24.02.0 1,195.6%   
Net profit margin %26.1-28.7 -91.1%  
BALANCE SHEET DATA
Current assets Rs m40,10511,014 364.1%   
Current liabilities Rs m6,59532,060 20.6%   
Net working cap to sales %82.5-108.1 -76.3%  
Current ratio x6.10.3 1,770.2%  
Inventory Days Days11995 124.9%  
Debtors Days Days8134 240.5%  
Net fixed assets Rs m19,99529,440 67.9%   
Share capital Rs m531705 75.4%   
"Free" reserves Rs m53,0432,043 2,596.8%   
Net worth Rs m53,5743,800 1,409.9%   
Long term debt Rs m09,018 0.0%   
Total assets Rs m61,58546,510 132.4%  
Interest coverage x618.4-0.2 -320,219.0%   
Debt to equity ratio x02.4 0.0%  
Sales to assets ratio x0.70.4 157.6%   
Return on assets %17.3-0.8 -2,270.3%  
Return on equity %19.8-146.9 -13.5%  
Return on capital %26.1-3.7 -698.5%  
Exports to sales %037.9 0.0%   
Imports to sales %25.222.6 111.6%   
Exports (fob) Rs mNA7,378 0.0%   
Imports (cif) Rs m10,2594,406 232.8%   
Fx inflow Rs m35,3847,513 470.9%   
Fx outflow Rs m10,3995,649 184.1%   
Net fx Rs m24,9851,865 1,340.0%   
CASH FLOW
From Operations Rs m11,4931,682 683.4%  
From Investments Rs m-11,372-9,860 115.3%  
From Financial Activity Rs m-936,644 -1.4%  
Net Cashflow Rs m28-1,535 -1.9%  

Share Holding

Indian Promoters % 52.0 32.3 161.0%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 11.8 4.6 256.5%  
FIIs % 19.0 3.3 575.8%  
ADR/GDR % 0.0 4.6 -  
Free float % 17.2 55.3 31.1%  
Shareholders   31,796 84,811 37.5%  
Pledged promoter(s) holding % 0.0 54.9 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare DIVIS LABORATORIES With:   PIRAMAL ENTERPRISES  GSK PHARMA  PANACEA BIOTECH  DR. REDDYS LAB  NOVARTIS  

Compare DIVIS LABORATORIES With:   MYLAN (US)  ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

Sensex Ends Above 35,000 Mark; Bank & IT Stocks Outperform(Closing)

After opening the day flat, share markets in India witnessed positive trading activity throughout the day and ended the day on a strong note.

Related Views on News

Shalby Ltd. (IPO)

Dec 2, 2017

Should you subscribe to the IPO of Shalby Ltd?

Sun Pharma: Tough US Scenario Continues to Hit Business (Quarterly Results Update - Detailed)

Nov 20, 2017

The company's India business recovers but the pricing pressure and USFDA issues continue to mar the US revenues.

Dr Reddy's: No Respite from Pricing Pressure in the US (Quarterly Results Update - Detailed)

Nov 13, 2017

Pricing pressure continued to haunt Dr Reddy's although there was a significant improvement in its businesses sequentially.

Cipla: Strong Recovery Post GST (Quarterly Results Update - Detailed)

Nov 10, 2017

Cipla's India business recovers strongly this quarter post the GST issues in the first quarter of this fiscal.

Glenmark: Most Geographies Show Weak Growth (Quarterly Results Update - Detailed)

Nov 7, 2017

Poor show in the US, Latam and India hit profits during the quarter.

More Views on News

Most Popular

Retail Investors or Chickens Waiting to Get Slaughtered in the Stock Market?(Vivek Kaul's Diary)

Jan 9, 2018

The price to earnings ratio of the Nifty 50 is very close to all-time high levels.

Is it Wise to Ignore Bitcoins?(The 5 Minute Wrapup)

Jan 4, 2018

While investing in bitcoins, it would make sense to treat it as another asset class and decide accordingly.

Best ELSS Funds In 2018: Don't Blindly Chase Top Performers(Outside View)

Jan 10, 2018

As the tax-saving season begins, investors hunt for the best ELSS funds for 2018. PersonalFN provides a list of the top ELSS mutual funds of the past year.

Resolutions for 2018 - by others(The Honest Truth)

Jan 8, 2018

Ten quirky new year resolutions. Guess by whom?

Bitcoin Beginners Should Do These Three Things...(Smart Contrarian)

Jan 10, 2018

Three simple points to keep in mind before you consider buying bitcoin.

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

DIVIS LABORATORIES SHARE PRICE


Jan 17, 2018 (Close)

TRACK DIVIS LABORATORIES

  • Track your investment in DIVIS LABORATORIES with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON DIVIS LABORATORIES

DIVIS LABORATORIES 5-YR ANALYSIS

COMPARE DIVIS LABORATORIES WITH

MARKET STATS